Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) General Counsel Patrick O’brien sold 14,625 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $60.12, for a total value of $879,255.00. Following the completion of the sale, the general counsel now owns 267,406 shares of the company’s stock, valued at $16,076,448.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of ARWR stock opened at $58.01 on Friday. The stock’s 50-day simple moving average is $64.25 and its 200-day simple moving average is $40.45. The firm has a market capitalization of $5.55 billion, a PE ratio of 84.07 and a beta of 1.97. Arrowhead Pharmaceuticals Inc has a fifty-two week low of $12.51 and a fifty-two week high of $73.72.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.03). The firm had revenue of $43.29 million during the quarter, compared to analyst estimates of $36.97 million. Arrowhead Pharmaceuticals had a net margin of 40.27% and a return on equity of 32.30%. On average, equities analysts expect that Arrowhead Pharmaceuticals Inc will post -0.36 earnings per share for the current year.
A number of research firms have commented on ARWR. S&P Equity Research reiterated a “buy” rating on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, November 26th. Piper Jaffray Companies increased their price target on Arrowhead Pharmaceuticals from $72.00 to $80.00 and gave the company an “overweight” rating in a research note on Monday, December 9th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $50.00 price target (up from $24.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, November 19th. B. Riley reiterated a “buy” rating and issued a $83.00 price target (up from $59.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 27th. Finally, Robert W. Baird upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their price target for the company from $39.00 to $70.00 in a research note on Monday, November 25th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $72.80.
Several hedge funds have recently made changes to their positions in ARWR. BlackRock Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 94.5% in the second quarter. BlackRock Inc. now owns 14,841,966 shares of the biotechnology company’s stock valued at $393,313,000 after purchasing an additional 7,210,892 shares during the period. Invesco Ltd. increased its holdings in shares of Arrowhead Pharmaceuticals by 550.5% in the second quarter. Invesco Ltd. now owns 4,820,607 shares of the biotechnology company’s stock valued at $127,747,000 after purchasing an additional 4,079,523 shares during the period. Vanguard Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 75.4% in the second quarter. Vanguard Group Inc. now owns 8,637,838 shares of the biotechnology company’s stock valued at $228,903,000 after purchasing an additional 3,712,392 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Arrowhead Pharmaceuticals by 184.3% in the second quarter. Bank of New York Mellon Corp now owns 1,063,856 shares of the biotechnology company’s stock valued at $28,193,000 after purchasing an additional 689,592 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 362.9% in the second quarter. Renaissance Technologies LLC now owns 788,800 shares of the biotechnology company’s stock valued at $20,903,000 after purchasing an additional 618,400 shares during the period. 70.39% of the stock is currently owned by institutional investors and hedge funds.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Story: What sectors are represented in the FTSE 100 index?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.